New Zealand (NZ) Otoplasty

All visitors who are not citizens of New Zealand need a passport to enter. Australian passport holders may enter New Zealand without a visa and stay as long as they wish without restrictions (including on employment). British passport holders can be granted a visa-free Visitor's Permit for up to six months on arrival. Citizens of a large number of other countries can be granted a visa-free visitor's entry for up to three months on arrival, check the list of Visa Free Countries. All these waivers, including the one for Australians, can be refused. In particular, potential visitors with criminal records or who have been refused entry to or deported from any country should check with New Zealand immigration about whether they need to apply for a visa.

Visitors from countries not in the visa-free list or those wishing to stay longer than the maximum visa-free period for their nationality, will need to apply for an appropriate visa. Check the Immigration New Zealand web page for details.

Context  Approval of drug-eluting coronary stents was based on results of relatively small trials of selected patients; however, in routine practice, stents are used in a broader spectrum of patients.

Objective  To compare the first 2 commercially available drug-eluting stents—sirolimus-eluting and paclitaxel-eluting—for prevention of symptom-driven clinical end points, using a study design reflecting everyday clinical practice.

Design, Setting, and Patients  Randomized, blinded trial conducted August 2004 to January 2006 at 5 university hospitals in Denmark. Patients were 2098 men and women (mean [SD] age, 63.6 [10.8] years) treated with percutaneous coronary intervention (PCI) and randomized to receive either sirolimus-eluting (n = 1065) or paclitaxel-eluting (n = 1033) stents. Indications for PCI included ST-segment elevation myocardial infarction (STEMI), non-STEMI or unstable angina pectoris, and stable angina.

Main Outcome Measures  The primary end point was a composite clinical end point of major adverse cardiac events, defined as either cardiac death, acute myocardial infarction, target lesion revascularization, or target vessel revascularization. Secondary end points included individual components of the composite end point, all-cause mortality, and stent thrombosis.

Results  The sirolimus- and the paclitaxel-eluting stent groups did not differ significantly in major adverse cardiac events (98 [9.3%] vs 114 [11.2%]; hazard ratio, 0.83 [95% confidence interval, 0.63-1.08]; P = .16) or in any of the secondary end points. The stent thrombosis rates were 27 (2.5%) and 30 (2.9%) (hazard ratio, 0.87 [95% confidence interval, 0.52-1.46]; P = .60), respectively.

Conclusion  In this practical randomized trial, there were no significant differences in clinical outcomes between patients receiving sirolimus- and paclitaxel-eluting stents.

Trial Registration  clinicaltrials.gov Identifier: NCT00388934